Genentech, Dako Submit Applications to FDA for Herceptin in HER2-Positive Stomach Cancer
June 02, 2010
Genentech, Dako Submit Applications to FDA for Herceptin in HER2-Positive Stomach Cancer
Hal Barron, Genentech's chief medical officer, said that "by using [Dako's] diagnostics to help identify the right patients" who will benefit from treatment, Genentech hopes to make Herceptin "the first targeted option for advanced HER2-positive stomach cancer."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Speeds New HER2-Targeted Drug and Companion Tests to Market
June 13, 2012 / Pharmacogenomics Reporter - Absent 'Gold Standard' for HER2 Testing, Researchers Question Role of Oncotype DX Beyond IHC/FISH
December 21, 2011 / Pharmacogenomics Reporter - Mayo Study Finds Expanded Protein Panel Fails to Predict Outcome of Herceptin Treatment
December 16, 2011 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - MDx/CDx Focus: EMA Okays Perjeta; Published Study on Prolaris; HER2 Tests for Kadcyla Clear FDA
March 6, 2013 / Pharmacogenomics Reporter